Abstract
Introduction: In ST-elevation myocardial infarction (STEMI), inflammation is pivotal, with early senescent CD4+CD28null cells implicated in its pathogenesis. However, the functional phenotype of these cells within the coronary circulation remains unclear. Methods: We examined CD4+ cell subpopulations in blood samples from the coronary sinus and vena cava of 24 STEMI patients and the cephalic vein of seven healthy controls. Results: Our findings revealed reduced CD4+ cell counts in STEMI patients compared to controls (1,998, 1,275–3,268 vs. 4,278, 3,595–4,449), alongside an increased proportion of CD4+ cells lacking CD28 expression (20.1 vs. 6.1%). These CD4+CD28null cells in STEMI predominantly exhibited a Th1 phenotype (47.8% vs. 6.6%). Intriguingly, no significant differences were detected in CD4+CD28null cells between coronary sinus and vena cava, and cytokine levels in these compartments remained similar. Conclusion: CD4+CD28null cells are increased in STEMI, mainly polarized toward a Th1 phenotype, and distributed equally between the different vascular beds.
Journal Section:
Rapid Communication
References
1.
Timmis
A
, Kazakiewicz
D
, Townsend
N
, Huculeci
R
, Aboyans
V
, Vardas
P
. Global epidemiology of acute coronary syndromes
. Nat Rev Cardiol
. 2023
;20
(11
):778
–88
. 2.
Thygesen
K
, Alpert
JS
, Jaffe
AS
, Chaitman
BR
, Bax
JJ
, Morrow
DA
, et al. Fourth universal definition of myocardial infarction (2018)
. J Am Coll Cardiol
. 2018
;72
(18
):2231
–64
. 3.
Olsen
MB
, Gregersen
I
, Sandanger
Ø
, Yang
K
, Sokolova
M
, Halvorsen
BE
, et al. Targeting the inflammasome in cardiovascular disease
. JACC Basic Transl Sci
. 2022
;7
(1
):84
–98
. 4.
Amezcua-Castillo
E
, González-Pacheco
H
, Sáenz-San Martín
A
, Méndez-Ocampo
P
, Gutierrez-Moctezuma
I
, Massó
F
, et al. C-reactive protein: the quintessential marker of systemic inflammation in coronary artery disease-advancing toward precision medicine
. Biomedicines
. 2023
;11
(9
):2444
. 5.
Libby
P
. Mechanisms of acute coronary syndromes and their implications for therapy
. N Engl J Med
. 2013
;368
(21
):2004
–13
. 6.
Amezcua-Guerra
B
, Amezcua-Castillo
LM
, Guerra-López
JA
, Díaz-Domínguez
KA
, Sánchez-Gloria
JL
, Cruz-Melendez
A
, et al. Diagnostic performance of serum MicroRNAs for ST-segment elevation myocardial infarction in the emergency department
. Biomedicines
. 2023
;11
(9
):2422
. 7.
Vallejo
AN
. CD28 extinction in human T cells: altered functions and the program of T-cell senescence
. Immunol Rev
. 2005
;205
:158
–69
. 8.
Bryl
E
, Vallejo
AN
, Weyand
CM
, Goronzy
JJ
. Down-regulation of CD28 expression by TNF-alpha
. J Immunol
. 2001
;167
(6
):3231
–8
. 9.
Amezcua-Guerra
LM
, Espinosa-Bautista
F
, Hopf-Estandía
K
, Valdivieso-Ruiz
M
, Coronel
D
, Robledo
S
, et al. Senescent CD4+CD28null cells are increased in chronic hyperuricemia, show aberrant effector phenotypes, and are reversed after allopurinol therapy: a proof-of-concept pilot study
. Clin Rheumatol
. 2023
;42
(8
):2181
–6
. 10.
Zhang
G
, Liu
Y
, Qiu
Y
, Zhang
J
, Sun
J
, Zhou
Z
, et al. Circulating senescent angiogenic T cells are linked with endothelial dysfunction and systemic inflammation in hypertension
. J Hypertens
. 2021
;39
(5
):970
–8
. 11.
Yadav
AK
, Lal
A
, Jha
V
. Cytotoxic CD4+CD28 null T lymphocytes, systemic inflammation and atherosclerotic risk in patients with chronic kidney disease
. Nephron Clin Pract
. 2012
;120
(4
):c185
–93
. 12.
Patlán
M
, Páez
A
, Massó
F
, Amezcua-Guerra
LM
. Relative increase of Th17 phenotype in senescent CD4+CD28null T cells from peripheral blood of patients with rheumatoid arthritis
. Clin Exp Rheumatol
. 2021
;39
(4
):925
–6
. 13.
Cossarizza
A
, Chang
HD
, Radbruch
A
, Abrignani
S
, Addo
R
, Akdis
M
, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
. Eur J Immunol
. 2021
;51
(12
):2708
–3145
. 14.
Liuzzo
G
, Kopecky
SL
, Frye
RL
, O’Fallon
WM
, Maseri
A
, Goronzy
JJ
, et al. Perturbation of the T-cell repertoire in patients with unstable angina
. Circulation
. 1999
;100
(21
):2135
–9
. 15.
Liuzzo
G
, Biasucci
LM
, Trotta
G
, Brugaletta
S
, Pinnelli
M
, Digianuario
G
, et al. Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events
. J Am Coll Cardiol
. 2007
;50
(15
):1450
–8
. 16.
Ruggio
A
, Pedicino
D
, Flego
D
, Vergallo
R
, Severino
A
, Lucci
C
, et al. Correlation between CD4+CD28null T lymphocytes, regulatory T cells and plaque rupture: an optical coherence tomography study in acute coronary syndromes
. Int J Cardiol
. 2019
;276
:289
–92
. 17.
Cheng
X
, Liao
YH
, Ge
H
, Li
B
, Zhang
J
, Yuan
J
, et al. TH1/TH2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation
. J Clin Immunol
. 2005
;25
(3
):246
–53
. 18.
Li
C
, Zong
W
, Zhang
M
, Tu
Y
, Zhou
Q
, Ni
M
, et al. Increased ratio of circulating T-helper 1 to T-helper 2 cells and severity of coronary artery disease in patients with acute myocardial infarction: a prospective observational study
. Med Sci Monit
. 2019
;25
:6034
–42
. 19.
Engelbertsen
D
, Andersson
L
, Ljungcrantz
I
, Wigren
M
, Hedblad
B
, Nilsson
J
, et al. T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke
. Arterioscler Thromb Vasc Biol
. 2013
;33
(3
):637
–44
. 20.
Zhao
Z
, Wu
Y
, Cheng
M
, Ji
Y
, Yang
X
, Liu
P
, et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome
. Atherosclerosis
. 2011
;217
(2
):518
–24
. 21.
Springall
R
, Amezcua-Guerra
LM
, Gonzalez-Pacheco
H
, Furuzawa-Carballeda
J
, Gomez-Garcia
L
, Marquez-Velasco
R
, et al. Interferon-gamma increases the ratio of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary artery disease
. PLoS One
. 2013
;8
(8
):e72291
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
